How to Cite
Abstract
Glioblastoma multiforme (GBM) is the most common and invasive poorly differentiated brain tumor with nearly 100 % rate of recurrence and unfavorable prognosis. The aim of the present review is to analyze recent studies and experimental results (Scopus, Web of Science, PubMed) concerning somatic mutations in glioblastoma, aberrant regulation of gene expression of signal pathways including EGFR, TGFß, etc. and markers for GBM progression. Particularly the molecular subtypes of glioblastoma and NGS results are considered in this review.References
Al-Mayhani M.T., Grenfell R., Narita M. et al. NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature // Neuro Oncol. - 2011. - Vol. 13. - № 8. - P. 830-845.
Arif S.H., Pandith A.A., Bhat A.R. et al. EGFR and PTEN gene mutation status in glioblastoma patients and their prognostic impact on patient's survival // J. Carcinog. Mutagen. - 2015. - Vol. 6. - P. 218.
Armstrong T.S., Prabhu S., Aldape K. et al. A case of soft tissue metastasis from glioblastoma and review of the literature // J. Neurooncol. - 2011. - Vol. 103. - P. 167- 172.
Balakrishnan A., Bleeker F.E., Lamba S. et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma // Cancer Res. - 2007. - Vol. 67. - P. 3545-3550.
Brennan C.W., Verhaak R.G.W., McKenna A. et al. The somatic genomic landscape of glioblastoma // Cell. - 2013. - Vol. 155. - P. 462-477.
Chamberlain M.C. Bevacizumab for the treatment of recurrent glioblastoma // Clin. Med. Insights Oncol. - 2011. - Vol. 5. - P. 117-129.
Chandran U.R., Luthra S., Santana-Santos L. et al. Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells // Genomics Data. - 2015. - Vol. 5. - P. 333-336.
Cohen A.L., Colman H. Glioma biology and molecular markers. In: Current understanding and treatment of gliomas. Cancer Treatment and Research. - 2015. - Vol. 163. - P. 15-30. Eds Raizer J., Parsa A. Springer International Publishing.
Combs S.E., Rieken S., Wick W. et al. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? // Radiat. Oncol. - 2011. - Vol. 6. - P. 115.
Diamandis P., Ferrer-Luna R., Huang R.Y et al. Case report: next generation sequencing identifies a NAB2-STAT6 fusion in glioblastoma // Diagn. Pathol. - 2016. - Vol. 11. - P. 13.
Fang X., Yoon J.G., Li L. et al. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis // BMC Genomics. - 2011. - Vol. 12. - P. 11.
Fontebasso A.M., Schwartzentruber J., Khuong-Quang D.A. et al. Mutations in SETD2 and genes affecting his-tone H3K36 methylation target hemispheric high-grade gliomas // Acta Neuropathol. - 2013. - Vol. 125. - P. 659-669.
Fontebasso A.M., Papillon-Cavanagh S., Schwartzentruber J. et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma // Nat. Genet. - 2014. - Vol. 46. - P. 462-466.
Hadjipanayis C.G., Van Meir E.G. Brain cancer propagating cells: biology, genetics and targeted therapies // Trends Mol. Med. - 2009. - Vol. 14. - P. 519-530.
Hodges T.R., Choi B.D., Bigner D.D. et al. Isocitrate dehydrogenase 1 (IDH1): what it means to the neurosurgeon // J. Neurosurg. - 2013. - Vol. 118. - № 6. - P. 1176-1180.
Holdhoff M., Yovino S., Boadu O., Grossman S.A. Blood-based biomarkers for malignant gliomas // J. Neurooncol. - 2013. - Vol. 113. - P. 345-352.
Ikushima H., Todo T., Ino Y et al. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein // J. Biol. Chem. - 2011. - Vol. 286. - P. 41434-41441.
Iwamoto F.M., Hormigo A. Unveiling YKL-40, from serum marker to target therapy in glioblastoma // Front. Oncol. - 2014. - Vol. 4. - P. 90.
Joseph J.V., Balasubramaniyan V., Walenkamp A., Kruyt F.A.E. TGF-ß as a therapeutic target in high grade gliomas - promises and challenges // Biochem. Pharmacol. - 2013. Vol. 85. - P. 478-485.
Kierulf-Vieira K.S., Sandberg C.J., Grieg Z. et al. Wnt inhibition is dysregulated in gliomas and its re-establishment inhibits proliferation and tumor sphere formation // Exp. Cell Res. - 2016. - Vol. 340. - P. 53-61.
Kruczyk M., Przanowski P., Dabrowski M. et al. Integration of genome-wide of STAT3 binding and epigenetic modification mapping with transcriptome reveals novel Stat3 target genes in glioma cells // Biochim. Biophys. Acta. - 2014. - Vol. 1839. - P. 1341-1350.
Lee H.K., Bier A., Cazacu S. et al. MicroRNA-145 is down-regulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor // Plos One. - 2013. - Vol. 8. - e54652.
Lee J.C., Vivanco I., Beroukhim R. et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain // PLoS Med. - 2006. - Vol. 3. - e485.
Lindsay A., Holthouse D., Robbins P., Knuckey N. Spinal leptomeningeal metastases following glioblastoma multiforme treated with radiotherapy // J. Clin. Neurosci. - 2002. - Vol. 9. - P. 725- 728.
Lo H.W., Cao X., Zhu H., Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators // Clin. Cancer Res. - 2008. - Vol. 14. - P. 6042-6054.
Lovejoy C.A., Li W., Reisenweber S. et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway // PLoS genet. - 2012. - Vol. 8. - e1002772.
Marziali G., Signore M., Buccarelli M. et al. Metabolic/proteomic signature defines two glioblastoma subtypes with different clinical outcome // Nat. Sci. Rep. - 2016. - Vol. 6. - P. 21557.
Maslehaty H., Cordovi S., Hefti M. Symptomatic spinal metastases of intracranial glioblastoma: clinical characteristics and pathomechanism relating to GFAP expression // J. Neurooncol. - 2011. - Vol. 101. - P. 329 -333.
Morokoff A., Ng W., Gogos A., Kaye A.H. Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma // J. Clin. Neurosci. - 2015. - Vol. 22. - P. 1219-1226.
Nicolaidis S. Biomarkers of glioblastoma multiforme // Metabolism. - 2015. - Vol. 64. - S22-7.
Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma // Am. J. Pathol. - 2007. - Vol. 170. - P. 1445-1453.
Ohgaki H., Kleihues P. The definition of primary and secondary glioblastoma // Clin. Cancer Res. - 2013. - Vol. 19. - № 4. - P. 764-772.
Olar A., Sulman E.P. Molecular markers in low-grade glioma - toward tumor reclassification // Semin. Radiat. Oncol. - 2015. - Vol. 25. - P. 155-163.
Paff M., Alexandru-Abrams D., Hsu F.P.K, Bota D.A. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients // Hum. Vaccin. Immunother. - 2014. - Vol. 10. - P. 3322-3331.
Patel R., Shervington A. Telomerase and DNA repair in glioma // Biochim. Biophys. Acta. - 2009. - Vol. 1792. - P. 275-279.
Rani S.B., Rathod S.S., Karthik S. et al. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells // Neuro Oncol. - 2013. - Vol. 15. - P. 1302-1316.
Reilly E.B., Phillips A.C., Buchanan F.G. et al. Characterization of ABT-806, a humanized tumor-specific anti-EG-FR moloclonal antibody // Mol. Cancer Ther. - 2015. - Vol. 14. - P. 1141-1151.
Rheinbay E., Suva M.L., Gillespie S.M. et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma // Cell Rep. - 2013. - Vol. 3. - P. 1567-1579.
Rivera A.L., Pelloski C.E., Sulman E., Aldape K. Prognostic and predictive markers in glioma and other neuroepithelial tumors // Curr. Probl. Cancer. - 2008. - Vol. 32. - P. 97-123.
Swartz A.M., Li Q.J., Sampson J.H. Rindopepimut: A promising immunotherapeutic for the treatment of glioblastoma multiforme // Immunotherapy. - 2014. - Vol. 6. - P. 679-690.
Taylor T.E., Furnari F.B., Cavenee W.B. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance // Curr. Cancer Drug Targets. - 2012. - Vol. 12. - P. 197-209.
Van Meir E.G., Hadjipanayis C.G., Norden A.D. et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma // CA-Cancer J. Clin. - 2010. - Vol. 60. - P. 166-193.
Verhaak R.G.W., Hoadley K.A., Purdom E. et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 // Cancer Cell. - 2010. - Vol. 17. - № 1. - P. 98.
Wang J., Su H-K., Zhao H-F. et al. Progress in the application of molecular biomarkers in gliomas // Biochem. Biophys. Res. Comm. - 2015. - Vol. 465. - P. 1-4.
Wang Z-H., Zhang Q-S., Duan Y-L. et al. TGF-ß induced miR-132 enhances the activation of TGF-ß signaling through inhibiting SMAD7 expression in glioma cells // Biochem. Biophys. Res. Commun. - 2015. - Vol. 463. - P. 187-192.
Wang Z-L., Zhang C-B., Cai J-Q. et al. Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHo II-IV gliomas // J. Exp. Clin. Cancer Res. - 2015. - Vol. 34. - P. 127.
Witt H., Mack S.C., Ryzhova M. et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma // Cancer Cell. - 2011. - Vol. 20. - P. 143-157.
Xu Y-R., Yang W-X. soX-mediated crosstalk during the progression of tumorigenesis // semin. Cell Dev. Biol. - 2016. - Vol. 63. - P. 23-34.
Yadavilli s., Hwang E.I., Packer R.J., Nazarian J. The role of NG2 proteoglycan in glioma // Transl. oncol. - 2016. - Vol. 9. - P 57-63.
Yang J., Liao D., Wang Z. et al. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis // J. surg. Res. - 2011. - Vol. 168. - P 97-102.
Yang Y, Shao N., Luo G. et al. Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate // Anticancer Res. - 2010. - Vol. 30. - P 981-985.
Zhang D.F., Li X.G., su L.J., Meng Q.L. Expression of activin A and follistatin in glioblastoma and their effects on U87 in vitro // J. Int. Med. Res. - 2010. - Vol. 38. - № 4. - P. 1343-1353.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017